GENE ONLINE|News &
Opinion
Blog

2025-05-02|

Amgen’s Biosimilar Revenue Boosted by $150 Million in Sales of J&J Copycat Drug in Q1

by Mark Chiang
Share To

NEWSFLASH

Amgen’s biosimilar business experienced a surge in revenue, driven in part by $150 million in first-quarter sales of its copycat version of Johnson & Johnson’s blockbuster medicine. The company’s biosimilar product, a direct competitor to a major Johnson & Johnson drug, contributed significantly to the overall growth of Amgen’s biosimilar division during the first three months of the year.

Newsflash | Powered by GeneOnline AI
Date: May 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-16
LATEST
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-16
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
Health Secretary Kennedy Retracts Parts of Agency Reorganization Plan During Combative Congressional Hearing
2025-05-14
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top